Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006

PHASE3CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Phenylketonuria
Interventions
DRUG

sapropterin dihydrochloride

5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.

Trial Locations (14)

Unknown

Los Angeles

Sacramento

San Jose

New Haven

Atlanta

Chicago

Minneapolis

St Louis

New York

Portland

Dallas

Salt Lake City

Seattle

Madison

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY